| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41572-018-0003-X |
| P698 | PubMed publication ID | 29977059 |
| P50 | author | Olivier Delattre | Q30119391 |
| Heinrich Kovar | Q41462089 | ||
| P2093 | author name string | Uta Dirksen | |
| Didier Surdez | |||
| Poul H. Sorensen | |||
| Enrique de Álava | |||
| Thomas G. P. Grünewald | |||
| Florencia Cidre-Aranaz | |||
| Eleni M. Tomazou | |||
| P2860 | cites work | Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite | Q22122062 |
| Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours | Q24298221 | ||
| JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor | Q24315882 | ||
| A new member of the ETS family fused to EWS in Ewing tumors | Q24317176 | ||
| MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells | Q24320635 | ||
| Condensin and cohesin complexity: the expanding repertoire of functions | Q24617076 | ||
| Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer | Q24625197 | ||
| CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis | Q24642797 | ||
| BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression | Q24650619 | ||
| Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting | Q26768602 | ||
| Targeting EZH2 in cancer | Q26769027 | ||
| The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease | Q26775306 | ||
| Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics | Q26776098 | ||
| Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation | Q26784048 | ||
| Novel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumors | Q27001114 | ||
| MicroRNA-34a: a potential therapeutic target in human cancer | Q27003249 | ||
| Ewing sarcoma cells secrete EWS/Fli-1 fusion mRNA via microvesicles | Q27303905 | ||
| EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma | Q27851507 | ||
| The genomic landscape of pediatric Ewing sarcoma | Q27853063 | ||
| High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation | Q28201421 | ||
| The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology | Q28239202 | ||
| The mechanisms behind the therapeutic activity of BET bromodomain inhibition | Q28241504 | ||
| A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG | Q28252253 | ||
| Histone methylation: a dynamic mark in health, disease and inheritance | Q28263573 | ||
| G-Protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcomas through PGF and MMP1 | Q28283859 | ||
| Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation | Q28302617 | ||
| Chromatin crosstalk in development and disease: lessons from REST | Q28306534 | ||
| Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation | Q28593817 | ||
| Caveolin-1 promotes Ewing sarcoma metastasis regulating MMP-9 expression through MAPK/ERK pathway | Q28816968 | ||
| Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma | Q29028729 | ||
| Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease | Q30315828 | ||
| YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. | Q30635379 | ||
| Realizing the promise of cancer predisposition genes | Q30743260 | ||
| Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study | Q33411585 | ||
| Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial | Q33416199 | ||
| The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function | Q33420364 | ||
| Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma | Q33597441 | ||
| Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow | Q33758219 | ||
| New strategies in ewing sarcoma: lost in translation? | Q33758471 | ||
| Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model | Q33798299 | ||
| What is the impact of local control in Ewing sarcoma: analysis of the first Brazilian collaborative study group - EWING1 | Q33805175 | ||
| Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors | Q33808340 | ||
| Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group | Q33813608 | ||
| The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation | Q33881163 | ||
| Modeling initiation of Ewing sarcoma in human neural crest cells | Q33894979 | ||
| Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro | Q33908885 | ||
| Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells | Q33992270 | ||
| Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial | Q33994512 | ||
| ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma | Q37424383 | ||
| BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma | Q37536618 | ||
| Non-coding RNAs as direct and indirect modulators of epigenetic regulation | Q37591537 | ||
| Widespread Chromatin Accessibility at Repetitive Elements Links Stem Cells with Human Cancer | Q37608149 | ||
| Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. | Q37624276 | ||
| SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions | Q37625383 | ||
| EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology | Q37672300 | ||
| CD99 polymorphisms significantly influence the probability to develop Ewing sarcoma in earlier age and patient disease progression | Q37718471 | ||
| Utility of bone marrow aspiration and biopsy in initial staging of Ewing sarcoma | Q38244942 | ||
| Stress-mediated translational control in cancer cells | Q38281204 | ||
| A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature | Q38293763 | ||
| Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma | Q38338166 | ||
| DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. | Q38373823 | ||
| Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. | Q38452580 | ||
| EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma. | Q38563638 | ||
| Ewing Sarcoma: Current Management and Future Approaches Through Collaboration | Q38573422 | ||
| Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth | Q38605150 | ||
| Update on Families of Round Cell Sarcomas Other than Classical Ewing Sarcomas. | Q38630100 | ||
| Regulation of gene transcription by Polycomb proteins | Q38668767 | ||
| EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma | Q38696838 | ||
| Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma. | Q38738129 | ||
| Micro-Environmental Stress Induces Src-Dependent Activation of Invadopodia and Cell Migration in Ewing Sarcoma | Q38749818 | ||
| Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States | Q38760598 | ||
| PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway | Q38830175 | ||
| Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma | Q38950669 | ||
| Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. | Q38981458 | ||
| Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma | Q39013447 | ||
| The Zyxin-related protein thyroid receptor interacting protein 6 (TRIP6) is overexpressed in Ewing's sarcoma and promotes migration, invasion and cell growth | Q39096397 | ||
| First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications. | Q39177112 | ||
| DKK2 mediates osteolysis, invasiveness, and metastatic spread in Ewing sarcoma | Q39233911 | ||
| Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma | Q39239580 | ||
| A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma | Q39331421 | ||
| A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion | Q39386166 | ||
| Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription. | Q39442604 | ||
| Germline Mutations in Predisposition Genes in Pediatric Cancer | Q36524309 | ||
| Recent advances in the molecular pathogenesis of Ewing's sarcoma | Q36562720 | ||
| Genomic EWS-FLI1 fusion sequences in Ewing sarcoma resemble breakpoint characteristics of immature lymphoid malignancies | Q36618540 | ||
| Prognostic impact of chromosomal aberrations in Ewing tumours | Q36644524 | ||
| MicroRNAs in Ewing Sarcoma | Q36722134 | ||
| Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma | Q36738866 | ||
| Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma | Q36756669 | ||
| Microsatellites as EWS/FLI response elements in Ewing's sarcoma | Q36786777 | ||
| Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. | Q36892577 | ||
| Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model | Q36970355 | ||
| ERBB4 confers metastatic capacity in Ewing sarcoma | Q37040838 | ||
| EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma | Q37135628 | ||
| Ewing sarcoma with ERG gene rearrangements: A molecular study focusing on the prevalence of FUS-ERG and common pitfalls in detecting EWSR1-ERG fusions by FISH | Q37222239 | ||
| Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer | Q37272420 | ||
| A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma | Q37421771 | ||
| Mesenchymal stem cell features of Ewing tumors | Q34003979 | ||
| Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway | Q34059738 | ||
| Emergent Properties of EWS/FLI Regulation via GGAA Microsatellites in Ewing's Sarcoma | Q34109415 | ||
| Cancer biology and NuRD: a multifaceted chromatin remodelling complex | Q34148512 | ||
| Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma | Q34166817 | ||
| Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study | Q34169663 | ||
| EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model | Q34206278 | ||
| Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. | Q34464009 | ||
| A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma | Q34532397 | ||
| Fractures in pediatric Ewing sarcoma | Q34569697 | ||
| Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006). | Q34636631 | ||
| Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone | Q34660467 | ||
| Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations | Q34691553 | ||
| Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing's sarcoma in the lung | Q34928239 | ||
| EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation | Q34963463 | ||
| Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group. | Q35007934 | ||
| Specific sites in the C terminus of CTCF interact with the SA2 subunit of the cohesin complex and are required for cohesin-dependent insulation activity | Q35096316 | ||
| Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis | Q35145374 | ||
| Macrophage infiltration predicts a poor prognosis for human ewing sarcoma | Q35168030 | ||
| Promiscuous partnerships in Ewing's sarcoma | Q35188770 | ||
| Targeting the DNA repair pathway in Ewing sarcoma | Q35283099 | ||
| Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma | Q35609719 | ||
| A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis | Q35665048 | ||
| Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group | Q35688154 | ||
| IL6 secreted by Ewing sarcoma tumor microenvironment confers anti-apoptotic and cell-disseminating paracrine responses in Ewing sarcoma cells | Q35717574 | ||
| High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases | Q35740170 | ||
| EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma | Q35820934 | ||
| The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting | Q35832365 | ||
| Mutational inactivation of STAG2 causes aneuploidy in human cancer | Q36029045 | ||
| EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors | Q36295912 | ||
| The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin | Q36326279 | ||
| Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. | Q36374350 | ||
| Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group | Q36389207 | ||
| A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome. | Q47149930 | ||
| CD99 at the crossroads of physiology and pathology | Q47203268 | ||
| Orthotopic patient-derived xenografts of paediatric solid tumours | Q47565470 | ||
| Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors | Q47605320 | ||
| Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma. | Q47703632 | ||
| Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. | Q47861303 | ||
| Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain. | Q47899647 | ||
| Molecular analysis of Ewing's sarcoma: another fusion gene, EWS-E1AF, available for diagnosis | Q48022580 | ||
| Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). | Q48324213 | ||
| Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets | Q49166444 | ||
| Can FDG-PET/CT replace blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma? | Q49199745 | ||
| PRDM9 and Its Role in Genetic Recombination | Q49796112 | ||
| Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas | Q50004172 | ||
| Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases | Q50182020 | ||
| Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. | Q50784397 | ||
| Epithelial-to-Mesenchymal and Mesenchymal-to-Epithelial Transition in Mesenchymal Tumors: A Paradox in Sarcomas? | Q51807220 | ||
| Review with novel markers facilitates precise categorization of 41 cases of diagnostically challenging, "undifferentiated small round cell tumors". A clinicopathologic, immunophenotypic and molecular analysis. | Q52584817 | ||
| Farm exposures, parental occupation, and risk of Ewing's sarcoma in Australia: a national case-control study. | Q52596389 | ||
| CD99: A Cell Surface Protein with an Oncojanus Role in Tumors. | Q52658031 | ||
| Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage? | Q52685529 | ||
| Ploidy and karyotype complexity are powerful prognostic indicators in the Ewing's sarcoma family of tumors: a study by the United Kingdom Cancer Cytogenetics and the Children's Cancer and Leukaemia Group. | Q52852427 | ||
| Molecular diagnosis of Ewing sarcoma family of tumors: a comparative analysis of 560 cases with FISH and RT-PCR. | Q53061514 | ||
| Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. | Q53453257 | ||
| EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. | Q53487773 | ||
| Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells. | Q54105269 | ||
| EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. | Q54158232 | ||
| A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Al | Q54355019 | ||
| Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. | Q54396439 | ||
| Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. | Q54797647 | ||
| Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol | Q56985814 | ||
| Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q57570627 | ||
| MIC2 is a specific marker for ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberrati | Q57756690 | ||
| EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. | Q59061840 | ||
| CIC-DUX4fusion-positive round-cell sarcomas of soft tissue and bone: a single-institution morphological and molecular analysis of seven cases | Q60628298 | ||
| Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation | Q60628603 | ||
| Chromosomes in Ewing's sarcoma. II. Nonrandom additional changes, trisomy 8 and der(16)t(1;16) | Q67920396 | ||
| [The German Society of Pediatric Oncology Cooperative Ewing Sarcoma Studies CESS 81/86: report after 6 1/2 years] | Q70416686 | ||
| Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors | Q71321688 | ||
| Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma | Q73810170 | ||
| A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells | Q74298025 | ||
| Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients | Q77302606 | ||
| Definitive radiotherapy for ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity | Q81211245 | ||
| Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells | Q81546174 | ||
| Intercellular junctions in Ewing sarcoma/primitive neuroectodermal tumor: additional evidence of epithelial differentiation | Q81791441 | ||
| Risk of recurrence and survival after relapse in patients with Ewing sarcoma | Q83731173 | ||
| Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005 | Q84110858 | ||
| Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support | Q84750681 | ||
| The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES) | Q84928460 | ||
| Time to diagnosis of ewing tumors in children and adolescents is not associated with metastasis or survival | Q85939579 | ||
| Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1 | Q87198365 | ||
| Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma | Q88948561 | ||
| STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors | Q39443702 | ||
| miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy | Q39465507 | ||
| 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma | Q39493814 | ||
| Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study | Q39538403 | ||
| EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma. | Q39634845 | ||
| Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients | Q39655936 | ||
| EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells | Q39716224 | ||
| Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition | Q39875012 | ||
| Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells | Q39915669 | ||
| No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients | Q39967014 | ||
| Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas | Q40045147 | ||
| Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial | Q40112795 | ||
| Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT. | Q40126904 | ||
| Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells | Q40135808 | ||
| A novel corepressor, BCoR-L1, represses transcription through an interaction with CtBP. | Q40155430 | ||
| Ewing's sarcoma in female siblings. A clinical report and review of the literature | Q40238817 | ||
| Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma. | Q40381404 | ||
| Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant. | Q40471939 | ||
| DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets | Q40490707 | ||
| Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells | Q40601528 | ||
| Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group | Q40755680 | ||
| Local control in Ewing sarcoma of the chest wall: results of the EURO-EWING 99 trial. | Q40806118 | ||
| Combinatorial generation of variable fusion proteins in the Ewing family of tumours. | Q40874946 | ||
| Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein | Q40925366 | ||
| Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis | Q40948678 | ||
| The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts | Q41072490 | ||
| The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis | Q41073699 | ||
| Gene knockout of Zmym3 in mice arrests spermatogenesis at meiotic metaphase with defects in spindle assembly checkpoint | Q41084001 | ||
| Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma. | Q41139182 | ||
| Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts | Q41155792 | ||
| Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells. | Q41224633 | ||
| The Neurological Compromised Spine Due to Ewing Sarcoma. What First: Surgery or Chemotherapy? Therapy, Survival, and Neurological Outcome of 15 Cases With Primary Ewing Sarcoma of the Vertebral Column. | Q41451017 | ||
| ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair | Q41967452 | ||
| Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation | Q42126638 | ||
| EWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between European and African populations. | Q42224745 | ||
| Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. | Q42379007 | ||
| MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research. | Q42385390 | ||
| Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. | Q43023369 | ||
| High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. | Q43626751 | ||
| FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. | Q43634477 | ||
| Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma | Q43699064 | ||
| The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma | Q43833260 | ||
| Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study | Q43873502 | ||
| An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma | Q43922197 | ||
| Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials | Q44263749 | ||
| Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma | Q44611540 | ||
| Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse | Q45230556 | ||
| Rarity of Ewing's sarcoma among U.S. Negro children | Q45242237 | ||
| Rarity of Ewing's tumour in Negroes | Q46761653 | ||
| Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. | Q46874365 | ||
| P433 | issue | 1 | |
| P921 | main subject | Ewing sarcoma | Q1138580 |
| P577 | publication date | 2018-07-05 | |
| P1433 | published in | Nature Reviews Disease Primers | Q24908540 |
| P1476 | title | Ewing sarcoma | |
| P478 | volume | 4 |
| Q90258362 | 18F-FDG PET-CT versus MRI for detection of skeletal metastasis in Ewing sarcoma |
| Q92343508 | A Fatal Case of Primary Orbital Ewing's Sarcoma with Intracranial Extensions in a Six-year-old Girl |
| Q89822311 | A Nonpediatric Extraosseous Ewing Sarcoma of the Pancreas: Differential Diagnosis and Therapeutic Strategies |
| Q101476552 | A framework for understanding the functions of biomolecular condensates across scales |
| Q64251223 | A nomogram to predict prognosis in Ewing sarcoma of bone |
| Q61807295 | Advances in immune checkpoint inhibitors for bone sarcoma therapy |
| Q90737255 | Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape |
| Q90237291 | Coding and non-coding drivers of mantle cell lymphoma identified through exome and genome sequencing |
| Q61810026 | Commentary |
| Q90068924 | Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes |
| Q64947686 | EWS-FLI1 low Ewing sarcoma cells demonstrate decreased susceptibility to T-cell-mediated tumor cell apoptosis. |
| Q91948077 | EWSR1/FUS-NFATc2 rearranged round cell sarcoma: clinicopathological series of 4 cases and literature review |
| Q92266003 | Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery |
| Q64113336 | Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force |
| Q89672116 | Ewing-like sarcomas: New molecular diagnoses in need of optimized treatment approaches |
| Q92812990 | Exosomes in Bone Sarcomas: Key Players in Metastasis |
| Q91957815 | Extraskeletal Ewing Sarcoma of the Jejunum: A Case Report |
| Q90270944 | High Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma |
| Q90279795 | High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008 |
| Q90087506 | Identifying prognosis and metastasis-associated genes associated with Ewing sarcoma by weighted gene co-expression network analysis |
| Q58080406 | Immunohistochemical Correlates of Recurrent Genetic Alterations in Sarcomas |
| Q112703882 | Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization |
| Q92987609 | MMP14 in Sarcoma: A Regulator of Tumor Microenvironment Communication in Connective Tissues |
| Q90110114 | Microenvironmental Factors Drive Tenascin C and Src Cooperation to Promote Invadopodia Formation in Ewing Sarcoma |
| Q91842359 | Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours |
| Q93196078 | NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker |
| Q92410968 | Oncogenic ETS Factors in Prostate Cancer |
| Q94948237 | Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma |
| Q90049793 | Risk factors for metastasis and poor prognosis of Ewing sarcoma: a population based study |
| Q99566252 | SOX6: a double-edged sword for Ewing sarcoma |
| Q64922004 | Successful embryo cryopreservation immediately following a full-term delivery in a woman with newly diagnosed Ewing's sarcoma. |
| Q90733025 | Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers |
| Q90344235 | Systemic therapy in pediatric-type soft-tissue sarcoma |
| Q61796850 | Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma |
| Q92865421 | Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies |
| Q90249624 | The Optimal Outcome of Suppressing Ewing Sarcoma Growth in vivo With Biocompatible Bioengineered miR-34a-5p Prodrug |
| Q104802882 | YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells |
| Q64121343 | and Gene Fusion-Associated Mesenchymal Tumors: Clinicopathologic Correlation and Literature Review |
| Q64375291 | A case of primary cutaneous Ewing sarcoma in a neutropenic patient |
| Q64251223 | A nomogram to predict prognosis in Ewing sarcoma of bone |
| Q64055912 | Anatomic Origin of Osteochondrogenic Progenitors Impacts Sensitivity to EWS-FLI1-Induced Transformation |
| Q64069784 | Cytogenetic characterization of the malignant primitive neuroectodermal SK-PN-DW tumor cell line |
| Q64113336 | Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force |
| Q64233967 | Glypican-3 expression in malignant small round cell tumors |
| Q64077124 | Predicting Ewing Sarcoma Treatment Outcome Using Infrared Spectroscopy and Machine Learning |
| Q64118178 | The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma |
| Q64267686 | Transcriptomic analysis functionally maps the intrinsically disordered domain of EWS/FLI and reveals novel transcriptional dependencies for oncogenesis |
Search more.